AltruBio

Biotech · Private

T-cell signaling modulators for autoimmune and inflammatory disease treatment

altrubio.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
13
2 granted · 11 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1351ADVAC, LLC——
1352CALEO BIOTECHNOLOGIES, INC.——
1353SOLVEXA, LLC——
1354AltruBio——
1355Allegro 3D, Inc.——
1356FoodSource Lure Corporation——
1357TANDA BIOTECH CORPORATION——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 2 granted of 13
  • Methods Of Using ANTI-PSGL-1 Antibodies In Combination With Jak Inhibitors To Treat T-cell Mediated Inflammatory Diseases Or Cancersapplication
  • Methods Of Using ANTI-PSGL-1 Antibodies In Combination With Jak Inhibitors To Treat T-cell Mediated Inflammatory Diseases Or Cancersgranted
  • Tetravalent ANTI-PSGL-1 Antibodies And Uses Thereofapplication
  • ANTI-PSGL-1 Antibodies And Uses Thereofapplication
  • Tetravalent ANTI-PSGL-1 Antibodies And Uses Thereofapplication
  • ANTI-PSGL-1 Antibodies And Uses Thereofgranted
  • Tetravalent ANTI-PSGL-1 Antibodies And Uses Thereofapplication
  • Methods Of Using Tetravalent ANTI-PSGL-1 Antibodies To Treat Ulcerative Colitisapplication
  • ANTI-PSGL-1 Antibodies And Uses Thereofapplication
  • Methods Of Using ANTI-PSGL-1 Antibodies In Combination With Jak Inhibitors To Treat T-cell Mediated Inflammatory Diseases Or Cancersapplication
  • Methods Of Using ANTI-PSGL-1 Antibodies In Combination With Jak Inhibitors To Treat T-cell Mediated Inflammatory Diseases Or Cancersapplication
  • Methods Of Using Tetravalent ANTI-PSGL-1 Antibodies To Treat Ulcerative Colitisapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.